Biostax (BTAX) 10-Q 2019 Q3 Quarterly report

Exhibit 32.1

CERTIFICATION

(1) In connection with the periodic report of Immune Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ending September 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), we, Michael Handley, Chief Executive Officer (Principal Executive Officer) and Peter Aronstam, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of our knowledge:1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: November 19, 2019	By:	/s/ Michael K. Handley
		Michael K. Handley
		Chief Executive Officer
		(Principal Executive Officer)
	By:	/s/ Peter Aronstam
		Peter Aronstam
		Chief Financial Officer
		(Principal Financial and Accounting Officer)